P. Buechner-Steudel

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).

V. Heinemann, T. Seufferlein, U. Martens, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC)

M. Egger, U. Martens, S. Wessendorf, 2015 .

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

A. Wein, W. Fleig, G. Kleber, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

O. Kuss, A. Wein, W. Fleig, 2009, British Journal of Cancer.

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

O. Kuss, A. Wein, W. Fleig, 2009, British Journal of Cancer.